Milestone Pharmaceuticals (NASDAQ:MIST) Stock Price Up 11.9% - Here's What Happened

Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report)'s stock price was up 11.9% during trading on Monday . The company traded as high as $2.21 and last traded at $2.17. Approximately 2,235,676 shares were traded during trading, an increase of 133% from the average daily volume of 960,207 shares. The stock had previously closed at $1.94.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on MIST shares. HC Wainwright upgraded shares of Milestone Pharmaceuticals to a "buy" rating and set a $5.00 price target on the stock in a report on Thursday, June 5th. TD Securities lowered shares of Milestone Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Tuesday, April 1st. TD Cowen lowered shares of Milestone Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, April 1st. Finally, Cowen lowered shares of Milestone Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Tuesday, April 1st. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. According to MarketBeat, Milestone Pharmaceuticals has a consensus rating of "Hold" and a consensus target price of $7.00.

Milestone Pharmaceuticals Price Performance

The business's 50 day moving average is $1.64 and its two-hundred day moving average is $1.70. The firm has a market cap of $83.40 million, a P/E ratio of -2.00 and a beta of 0.96. The company has a quick ratio of 4.67, a current ratio of 4.67 and a debt-to-equity ratio of 4.06.

Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) last announced its earnings results on Wednesday, May 14th. The company reported ($0.31) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.12). As a group, analysts anticipate that Milestone Pharmaceuticals Inc. will post -0.62 earnings per share for the current year.

Institutional Investors Weigh In On Milestone Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. Jones Financial Companies Lllp increased its position in shares of Milestone Pharmaceuticals by 1,000.0% during the fourth quarter. Jones Financial Companies Lllp now owns 11,000 shares of the company's stock worth $26,000 after acquiring an additional 10,000 shares in the last quarter. Bay Rivers Group bought a new stake in shares of Milestone Pharmaceuticals during the second quarter worth about $28,000. XTX Topco Ltd boosted its holdings in Milestone Pharmaceuticals by 52.7% during the first quarter. XTX Topco Ltd now owns 52,004 shares of the company's stock worth $42,000 after purchasing an additional 17,950 shares during the last quarter. National Bank of Canada FI boosted its holdings in Milestone Pharmaceuticals by 163.4% during the fourth quarter. National Bank of Canada FI now owns 18,700 shares of the company's stock worth $44,000 after purchasing an additional 11,600 shares during the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new position in Milestone Pharmaceuticals during the fourth quarter worth about $73,000. 86.18% of the stock is owned by institutional investors.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.